NCT07125729View on ClinicalTrials.gov

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

NARecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 12, 2025

Primary Completion Date

January 9, 2028

Study Completion Date

January 9, 2028

Conditions
Resectable Colorectal CarcinomaStage II Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo archival tissue and/or blood sample collection

OTHER

cfDNA or ctDNA Measurement

Undergo Haystack MRD and Signatera ctDNA/cfDNA testing

OTHER

Electronic Health Record Review

Ancillary studies

Trial Locations (13)

30265

RECRUITING

City of Hope Atlanta Cancer Center, Newnan

60099

RECRUITING

City of Hope at Chicago, Zion

85338

RECRUITING

CTCA at Western Regional Medical Center, Goodyear

90503

RECRUITING

City of Hope South Bay, Torrance

90813

RECRUITING

City of Hope at Long Beach Elm, Long Beach

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

91030

RECRUITING

City of Hope South Pasadena, South Pasadena

91786

RECRUITING

City of Hope Upland, Upland

92618

RECRUITING

City of Hope at Irvine Lennar, Irvine

92648

RECRUITING

City of Hope Seacliff, Huntington Beach

92660

RECRUITING

City of Hope at Newport Beach Fashion Island, Newport Beach

92882

RECRUITING

City of Hope Corona, Corona

93534

RECRUITING

City of Hope Antelope Valley, Lancaster

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT07125729 - Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients | Biotech Hunter | Biotech Hunter